Storia in 4 fonti

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 g fa

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson

J&J commits $3.5B for oncology—$1B Firefly Bio buy plus $2.58B Sail partnership option—targeting KRAS-driven solid tumors. The deal underscores biotech M&A competition as startups command higher valuations; 2026 EPS drag estimated at $0.46.

originale

Timeline cronologica

giovedì 30 luglio 2026·morningstar.com
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
giovedì 30 luglio 2026·biopharmadive.com
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson

Confronto fonti

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson

Timeline cronologica

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech

J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech

Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals - Johnson & Johnson

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson